Kidney Cancer clinical trials in Delaware

8 actively recruiting kidney cancer trials at 5 sites across Delaware.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 2, Phase 3 Recruiting NIH

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05987241

Sites in Delaware:

Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, su…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT06661720

Sites in Delaware:

Beebe South Coastal Health Campus — Millville, Delaware
Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware
Beebe Health Campus — Rehoboth Beach, Delaware

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with re…

Sponsor: NRG Oncology

NCT ID: NCT05327686

Sites in Delaware:

Beebe Medical Center — Lewes, Delaware
Beebe South Coastal Health Campus — Millville, Delaware
Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware
Christiana Care Health System-Christiana Hospital — Newark, Delaware

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Dru…

Sponsor: Children's Oncology Group

NCT ID: NCT04322318

Sites in Delaware:

Alfred I duPont Hospital for Children — Wilmington, Delaware

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis

NCT ID: NCT05176483

Sites in Delaware:

Exelixis Clinical Site #49 — Newark, Delaware

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc

NCT ID: NCT04485013

Sites in Delaware:

Christiana Care Helen F. Graham Cancer Center — Newark, Delaware

View on ClinicalTrials.gov →

Recruiting Network

Project: Every Child for Younger Patients With Cancer

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going ca…

Sponsor: Children's Oncology Group

NCT ID: NCT02402244

Sites in Delaware:

Alfred I duPont Hospital for Children — Wilmington, Delaware

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Delaware:

Massive Bio SYNERGY-AI site — Newark, Delaware

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20